Executive Summary: BPC-157 in Orthopaedic and Sports Medicine (PMC12313605)

doi: 10.1177/15563316251355551

1. Background & Regulatory Status

• Nature: A 15-amino-acid peptide endogenously produced in human gastric juice, primarily known for maintaining gastrointestinal mucosal integrity and systemic homeostasis.
• Clinical Use & Controversy: Not approved by the U.S. FDA, but widely used off-label by clinicians for joint injections and by athletes for musculoskeletal injury recovery. It is marketed online as a “dietary supplement” or “research chemical.”
• Ban Status: Classified as a prohibited substance by WADA, the NFL, and the UFC since 2022. Public interest has surged, with peak Google Search volume in 2024 and over 50 million views of related social media content.

2. Core Mechanisms of Action (Preclinical Evidence)

1. Angiogenesis & Proliferation: Upregulates VEGF to promote blood vessel formation; activates ERK1/2, AKT, and KRAS signaling to accelerate cell proliferation and migration; enhances growth hormone receptor expression and FAK-paxillin pathway activity to improve tenocyte survival and adhesion.
2. Anti-Inflammatory & Vascular Regulation: Inhibits pro-inflammatory mediators (COX-2, IL-6, TNF-α) and myeloperoxidase activity; upregulates nitric oxide synthase (NOS) to boost NO production, improving vasodilation and tissue perfusion.
3. Neuromodulation: Modulates dopamine and serotonin pathways, potentially contributing to pain relief and neuroprotection.

3. Musculoskeletal Efficacy (Preclinical vs. Clinical)

Preclinical Efficacy (Animal/Cell Models)

• Muscle Injuries: Improves structural integrity and biomechanical strength after transection or crush injuries; reduces muscle atrophy and accelerates functional recovery—even in the presence of glucocorticoid-induced impairment.
• Tendon/Ligament Injuries: Accelerates healing of Achilles and quadriceps tendons; enhances tendon-bone junction repair; restores biomechanical strength of ligaments (e.g., medial collateral ligament) and reduces inflammatory infiltration.
• Bone Injuries: Promotes callus mineralization and lamellar bone formation in rabbit nonunion models, with efficacy comparable to autologous bone marrow injection or autograft.
• Arthritis: Reduces joint swelling, nodule formation, and stiffness in experimental arthritis models.

Clinical Evidence (Extremely Limited)

• Only 1 retrospective clinical study was identified: 12 patients with chronic knee pain received intra-articular BPC-157 injections, with 7 reporting sustained symptom relief for over 6 months. No large-scale, randomized controlled trials (RCTs) exist to confirm these findings.

4. Pharmacokinetics & Detection

• Metabolism & Excretion: Metabolized primarily in the liver via the cytochrome P450 system; excreted through the kidneys, with the highest tissue concentrations in the kidneys and liver.
• Pharmacokinetics: Short half-life (<30 minutes) with linear kinetics.
• Doping Detection: Metabolites are stably detectable in urine for 4–5 days at low thresholds (0.03–0.11 ng/mL), well below WADA’s minimum required performance level (2 ng/mL), enabling reliable anti-doping testing.

5. Safety & Risks

Preclinical Safety

• No acute toxicity, mutagenicity, or teratogenicity was observed in rats and dogs across doses of 6 μg/kg to 20 mg/kg (administered for up to 6 weeks via IM, IV, or oral routes).
• Demonstrated hepatoprotective effects in preclinical models.

Clinical Risks (Critical Gaps)

• No Long-Term Human Data: Safety profiles in humans remain uncharacterized due to the absence of RCTs.
• Product Contamination: 12%–58% of unregulated “BPC-157 supplements” are reported to contain contaminants, posing unforeseen health risks.
• Reported Adverse Events: Users have documented injection-site swelling, joint pain, anxiety, and palpitations—likely linked to product contamination or off-target pathway modulation.

6. Conclusions & Recommendations

Core Conclusion

Key Recommendations

1. Athletes: Adhere strictly to anti-doping regulations (WADA/NFL/UFC) to avoid sanctions.
2. Clinicians: Exercise extreme caution when using BPC-157 off-label; conduct thorough assessments of patients’ supplement use and warn against unregulated products.
3. Research Community: Prioritize large-scale, long-term RCTs to establish BPC-157’s efficacy, optimal dosing, and safety profile in human populations.